422 related articles for article (PubMed ID: 31608511)
21. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions.
Barbaud A; Collet E; Milpied B; Assier H; Staumont D; Avenel-Audran M; Grange A; Amarger S; Girardin P; Guinnepain MT; Truchetet F; Lasek A; Waton J;
Br J Dermatol; 2013 Mar; 168(3):555-62. PubMed ID: 23136927
[TBL] [Abstract][Full Text] [Related]
22. Severe delayed skin reactions related to drugs in the paediatric age group: A review of the subject by way of three cases (Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS).
Belver MT; Michavila A; Bobolea I; Feito M; Bellón T; Quirce S
Allergol Immunopathol (Madr); 2016; 44(1):83-95. PubMed ID: 26089185
[TBL] [Abstract][Full Text] [Related]
23. Acute generalized exanthematous pustulosis and Stevens-Johnson syndrome overlap due to hydroxychloroquine: a case report.
Coleman I; Ruiz G; Brahmbhatt S; Ackerman L
J Med Case Rep; 2020 Nov; 14(1):210. PubMed ID: 33138853
[TBL] [Abstract][Full Text] [Related]
24. Treatment of toxic epidermal necrolysis by a multidisciplinary team. A review of literature and treatment results.
Papp A; Sikora S; Evans M; Song D; Kirchhof M; Miliszewski M; Dutz J
Burns; 2018 Jun; 44(4):807-815. PubMed ID: 29627131
[TBL] [Abstract][Full Text] [Related]
25. Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy.
Pavlos R; Mallal S; Ostrov D; Pompeu Y; Phillips E
J Allergy Clin Immunol Pract; 2014; 2(1):21-33. PubMed ID: 24565765
[TBL] [Abstract][Full Text] [Related]
26. Drug Hypersensitivity Reactions.
Wilkerson RG
Immunol Allergy Clin North Am; 2023 Aug; 43(3):473-489. PubMed ID: 37394254
[TBL] [Abstract][Full Text] [Related]
27. Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
Lerch M; Mainetti C; Terziroli Beretta-Piccoli B; Harr T
Clin Rev Allergy Immunol; 2018 Feb; 54(1):147-176. PubMed ID: 29188475
[TBL] [Abstract][Full Text] [Related]
28. Severe cutaneous reactions to drugs in the setting of a general hospital.
Grando LR; Schmitt TA; Bakos RM
An Bras Dermatol; 2014; 89(5):758-62. PubMed ID: 25184915
[TBL] [Abstract][Full Text] [Related]
29. Severe Cutaneous Adverse Drug Reactions at a Tertiary Care Center in Saudi Arabia.
AlJasser MI
Dermatol Res Pract; 2023; 2023():8928198. PubMed ID: 37206671
[TBL] [Abstract][Full Text] [Related]
30. Severe flucloxacillin-induced acute generalized exanthematous pustulosis (AGEP), with toxic epidermal necrolysis (TEN)-like features: does overlap between AGEP and TEN exist? Clinical report and review of the literature.
van Hattem S; Beerthuizen GI; Kardaun SH
Br J Dermatol; 2014 Dec; 171(6):1539-45. PubMed ID: 24888401
[TBL] [Abstract][Full Text] [Related]
31. Skin tests in the work-up of cutaneous adverse drug reactions: A review and update.
Barbaud A; Castagna J; Soria A
Contact Dermatitis; 2022 May; 86(5):344-356. PubMed ID: 35122269
[TBL] [Abstract][Full Text] [Related]
32. Retrospective study of 213 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis from China.
Yang L; Shou YH; Li F; Zhu XH; Yang YS; Xu JH
Burns; 2020 Jun; 46(4):959-969. PubMed ID: 31898979
[TBL] [Abstract][Full Text] [Related]
33. Medication Associations With Severe Cutaneous Adverse Reactions: A Case/Non-Case Analysis Using the FDA Adverse Event Reporting System.
Godfrey H; Jedlowski P; Thiede R
J Cutan Med Surg; 2024; 28(1):51-58. PubMed ID: 38189282
[TBL] [Abstract][Full Text] [Related]
34. Outpatient management and follow-up recommendations for adverse drug reactions: guidelines for posthospitalization care.
Khanna R; Vaudreuil A; Lake E
Cutis; 2019 May; 103(5):254-256;258. PubMed ID: 31233575
[TBL] [Abstract][Full Text] [Related]
35. Clinical features and prognostic factors of severe cutaneous adverse drug reactions: A single-center retrospective study of 209 cases in China.
Deng M; Su Y; Wu R; Li S; Tang G; Kuang Q; Luo X; Zhu Y; Shen W
Int Immunopharmacol; 2023 Jan; 114():109530. PubMed ID: 36508915
[TBL] [Abstract][Full Text] [Related]
36. Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of the experience with paediatric patients in a university hospital.
Ferrándiz-Pulido C; García-Fernández D; Domínguez-Sampedro P; García-Patos V
J Eur Acad Dermatol Venereol; 2011 Oct; 25(10):1153-9. PubMed ID: 21198948
[TBL] [Abstract][Full Text] [Related]
37. Profile and pattern of Stevens-Johnson syndrome and toxic epidermal necrolysis in a general hospital in Singapore: treatment outcomes.
Tan SK; Tay YK
Acta Derm Venereol; 2012 Jan; 92(1):62-6. PubMed ID: 21710108
[TBL] [Abstract][Full Text] [Related]
38. Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis.
Wolkenstein P; Chosidow O; Fléchet ML; Robbiola O; Paul M; Dumé L; Revuz J; Roujeau JC
Contact Dermatitis; 1996 Oct; 35(4):234-6. PubMed ID: 8957644
[TBL] [Abstract][Full Text] [Related]
39. An epidemiological and clinical analysis of cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia.
Choon SE; Lai NM
Indian J Dermatol Venereol Leprol; 2012; 78(6):734-9. PubMed ID: 23075643
[TBL] [Abstract][Full Text] [Related]
40. Severe cutaneous adverse reactions: acute generalized exanthematous pustulosis, toxic epidermal necrolysis and Stevens-Johnson syndrome.
Harr T; French LE
Med Clin North Am; 2010 Jul; 94(4):727-42, x. PubMed ID: 20609860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
